GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (FRA:BS50) » Definitions » Cyclically Adjusted Price-to-FCF

Inotiv (FRA:BS50) Cyclically Adjusted Price-to-FCF : (As of Jun. 20, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inotiv Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Inotiv's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Cyclically Adjusted Price-to-FCF Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.37 - - - -

Inotiv Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inotiv's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Inotiv's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Inotiv's Cyclically Adjusted Price-to-FCF falls into.



Inotiv Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Inotiv's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Inotiv's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.352/131.7762*131.7762
=0.352

Current CPI (Mar. 2024) = 131.7762.

Inotiv Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.001 100.560 0.001
201409 0.031 100.428 0.041
201412 -0.024 99.070 -0.032
201503 0.056 99.621 0.074
201506 0.030 100.684 0.039
201509 0.013 100.392 0.017
201512 -0.058 99.792 -0.077
201603 0.001 100.470 0.001
201606 -0.007 101.688 -0.009
201609 0.041 101.861 0.053
201612 0.099 101.863 0.128
201703 -0.054 102.862 -0.069
201706 0.064 103.349 0.082
201709 -0.014 104.136 -0.018
201712 0.056 104.011 0.071
201803 -0.016 105.290 -0.020
201806 0.091 106.317 0.113
201809 0.074 106.507 0.092
201812 0.019 105.998 0.024
201903 -0.132 107.251 -0.162
201906 -0.140 108.070 -0.171
201909 -0.185 108.329 -0.225
201912 -0.060 108.420 -0.073
202003 -0.191 108.902 -0.231
202006 -0.041 108.767 -0.050
202009 -0.108 109.815 -0.130
202012 0.013 109.897 0.016
202103 0.145 111.754 0.171
202106 -0.130 114.631 -0.149
202109 -0.073 115.734 -0.083
202112 -0.285 117.630 -0.319
202203 -0.157 121.301 -0.171
202206 -0.945 125.017 -0.996
202209 -0.191 125.227 -0.201
202212 -0.582 125.222 -0.612
202303 0.159 127.348 0.165
202306 -0.028 128.729 -0.029
202309 0.463 129.860 0.470
202312 -0.431 129.419 -0.439
202403 0.352 131.776 0.352

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inotiv  (FRA:BS50) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Inotiv Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Inotiv's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (FRA:BS50) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (FRA:BS50) Headlines

No Headlines